Advanced in Perlman Syndrome
Advanced in Perlman Syndrome
Lpch Medical Group Div Of Lucile
725 Welch Rd, 
Palo Alto, CA 

Overview

Jay Balagtas is a Pediatric Hematologist Oncology provider in Palo Alto, California. Dr. Balagtas is rated as an Advanced provider by MediFind in the treatment of Perlman Syndrome. His top areas of expertise are Hepatoblastoma, Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Ewing Sarcoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 40 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 6 Less Insurance Carriers -

Locations

LPCH MEDICAL GROUP DIV OF LUCILE
725 Welch Rd, Palo Alto, CA 94304

Additional Areas of Focus

Dr. Balagtas has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


40 Clinical Trials

Neuroblastoma Biology Studies
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
Key Adverse Events After Childhood Cancer
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age
View 39 Less Clinical Trials
Similar Doctors
Advanced in Perlman Syndrome
Pediatric Hematology Oncology
Advanced in Perlman Syndrome
Pediatric Hematology Oncology
725 Welch Rd, 
Palo Alto, CA 
 (0.1 miles away)
Languages Spoken:
English

Raya Saab is a Pediatric Hematologist Oncology provider in Palo Alto, California. Dr. Saab is rated as a Distinguished provider by MediFind in the treatment of Perlman Syndrome. Her top areas of expertise are Rhabdomyosarcoma, Retinoblastoma, Osteosarcoma, and Ewing Sarcoma.

Advanced in Perlman Syndrome
Pediatric Hematology Oncology
Advanced in Perlman Syndrome
Pediatric Hematology Oncology
725 Welch Rd, 
Palo Alto, CA 
 (0.1 miles away)
Languages Spoken:
English

Allison Pribnow is a Pediatric Hematologist Oncology provider in Palo Alto, California. Dr. Pribnow is rated as an Advanced provider by MediFind in the treatment of Perlman Syndrome. Her top areas of expertise are Osteosarcoma, Ewing Sarcoma, Hodgkin Lymphoma, and Hepatoblastoma.

Advanced in Perlman Syndrome
Pediatric Hematology Oncology
Advanced in Perlman Syndrome
Pediatric Hematology Oncology
1000 Welch Rd, Ste 300 MC 5798, 
Palo Alto, CA 
 (0.2 miles away)
Languages Spoken:
English

Avanthi Shah is a Pediatric Hematologist Oncology provider in Palo Alto, California. Dr. Shah is rated as a Distinguished provider by MediFind in the treatment of Perlman Syndrome. Her top areas of expertise are Osteosarcoma, Hepatoblastoma, Neuroblastoma, Ewing Sarcoma, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Balagtas's expertise for a condition
ConditionClose
    View All 25 Advanced Conditions
    View All 35 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile